Abstract:<p>Chemotherapeutic strategy has been widely used for treating malignance by targeting irregular expressed or mutant proteins with small molecular inhibitors (SMIs) or monoclonal antibodies (mAbs). However, most intracellular proteins lack of active sites or antigens where SMIs or mAbs bind with, and are called as non-druggable targets for a long time. From the first year of this century, PROteolysis-TArgeting Chimeras (PROTACs) has emerged to be a promising approach for proteins, including those non-druggable ones, such as transcriptional factors and scaffold proteins. The first generation of peptide-based PROTACs adopts β-TrCP and VHL as E3 ligases, but the cellular permeability and chemical stability issues restrict their clinical application. The second generation of small molecule-based PROTACs adopts MDM2, VHL, IAPs and Cereblon as E3 ligases have been tensely studied. To date, the targets of PROTACs including those overexpressed oncogenic proteins such as ER, AR and BRDs, disease-relevant fusion proteins such as NPM/EML4-ALK and BCL-ABL, cancer-driven mutant proteins such as EGFR, kinases such as CDKs and RTKs. The major disadvantage of PROTACs is the noncancer specificity and relative higher toxicity, due to its catalytic role. To overcome this, we and other have recently developed several similar light-controllable PROTACs, termed as the third generation controllable PROTACs. The degradation of targets by those PROTACs can be triggered by UVA or visible light, providing a tool box for further PROTACs design. Here in this review, we introduce the historical milestones and prospective for further PROTACs development in clinical use.</p>

Selective Proteolysis of Activated Transcriptional Factor by NIR‐Responsive Palindromic DNA Thalidomide Conjugate Inhibits the Canonical Smad Pathway

PROTACs: an Emerging Targeting Technique for Protein Degradation in Drug Discovery

TF-PROTACs Enable Targeted Degradation of Transcription Factors.

Targeted dephosphorylation of SMAD3 as an approach to impede TGF-β signaling

Targeted Degradation of Transcription Factors by TRAFTACs: Transcription Factor Targeting Chimeras

MicroRNA‐Triggered Programmable DNA‐Encoded Pre‐PROTACs for Cell‐Selective and Controlled Protein Degradation

Destruction of DNA‐Binding Proteins by Programmable Oligonucleotide PROTAC (O'PROTAC): Effective Targeting of LEF1 and ERG

Precise Modulation of Protein Degradation by Smart PROTACs

PROTACs: A novel strategy for cancer therapy

Targeting Undruggable Transcription Factors with PROTACs: Advances and Perspectives

DNA-templated spatially controlled proteolysis targeting chimeras for CyclinD1-CDK4/6 complex protein degradation

Stimuli-activatable PROTACs for precise protein degradation and cancer therapy

Photo-regulated PROTACs: A novel tool for temporal control of targeted protein degradation

Discovery of thalidomide-based PROTAC small molecules as the highly efficient SHP2 degraders

[Induced degradation of proteins by PROTACs and other strategies: towards promising drugs]

PROTACs: New method to degrade transcription regulating proteins

Bifunctional Peptide Nanofibrils for Targeted Protein Degradation.

Targeted Protein Degradation by Chimeric Small Molecules, PROTACs and SNIPERs

In Vivo Target Protein Degradation Induced by PROTACs Based on E3 Ligase DCAF15

Light-induced Control of Protein Destruction by Opto-Protac.

An overview of PROTACs: a promising drug discovery paradigm